ADHD

In a recent study, pediatric patients with ADHD were less likely to be hospitalized from a mental disorder or need stimulant prescriptions when given general practitioner centered primary care.

A recent study independently associated maternal obesity with ADHD risk in offspring, with a significant risk observed in joint obesity and excessive weight gain.

In a recent study, children with ADHD were slower to reorient when looking at images of faces than children without ADHD.

ADHD has been linked with greater perceived stress and sleep problems in adolescents.

The results show pediatric patients with ADHD had a significantly higher risk of injuries requiring hospitalization compared to non-ADHD controls.

Older participants had smaller dual-task performance deficits for gait and texting speed in both the ADHD group and the control group.

A recent review suggests that atomoxetine can reduce symptoms of anxiety in children and adolescents with ADHD.

A recent study showed no correlation between prenatal exposure to triptans and diagnosis or symptoms of ADHD in children.

Investigators found that symptoms of attention-deficit/hyperactivity disorder were more often seen in children with a lower birth weight.

Treatments for ADHD proved to be the most effective in reducing the risks of developing substance use disorders.

Symptoms, evaluation, and treatment of ADHD.

How can we help this unique patient population thrive? Experts weigh in at the 2022 APA Annual Meeting.

What are the unique challenges for individuals with ADHD?

At the 2022 Pediatric Academic Societies meeting, Shruti Mittal, MD, FAAP, looked at how many children with attention-deficit/hyperactivity disorder get started on behavioral therapy before medication in the preschool years.

At the 43rd National Conference on Pediatric Health Care for nurse practitioners in Dallas, Texas, a look at the newest medications for children with attention-deficit/hyperactivity disorder.

Catch up on all the latest in ADHD from the The American Professional Society of ADHD (attention-deficit/hyperactivity disorder) and Related Disorders (APSARD) virtual 2022 Annual Meeting.

In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension in patients with attention-deficit/hyperactivity disorder (ADHD) by the US Food and Drug Administration (FDA).

At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, Grace Wang, MD, FAAP, discusses how treatment of underlying sleep disorders can improve ADHD symptomatology.

A study has found that prenatal analgesic opioid exposure of 5 or more weeks is associated with a slightly elevated risk of attention-deficit/hyperactivity disorder (ADHD) in children compared to exposure of 4 weeks or less.

AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is available for prescription to help provide rapid and extended duration of attention-deficit/hyperactivity disorder (ADHD) symptoms.

A study examines the effect of after-school activity participation on a child's attention-deficit/hyperactivity disorder (ADHD) severity.

Stimulants are recommended as the first-line treatment for attention-deficit/hyperactivity disorder (ADHD). A study examines whether α2-adrenergic agonists could be effective as well.

A study examines if promoting positive behaviors including masking leads to improved face covering in children with autism spectrum disorder and/or attention-deficit/hyperactivity disorder.

The US Food and Drug Administration (FDA) approves first novel non-stimulant medication to treat attention-deficit/hyperactivity disorder (ADHD) in children in a decade.

Unfortunately, disparities in health care are nothing unusual. A report examines if there are disparities in attention-deficit/hyperactivity disorder (ADHD) diagnosis and treatment due to race and ethnicity.